Loss of appetite during illness is a common and potentially debilitating phenomenon—in cancer patients, especially, it can even shorten lifespan. Researchers of the Scripps Research Institute (TSRI) have discovered how an immune system molecule hijacks a brain circuit and reduces appetite. Their discovery points to possible targets for treating loss of appetite and restoring a patient’s strength.
Boston Scientific get U.S. Food and Drug Administration (FDA) approval for two catheters that can be used with the Rhythmia™ Mapping System. The IntellaNav™ XP and the IntellaNav MiFi™ XP navigation-enabled ablation catheters were approved to treat Type I atrial flutter. These are the first magnetically-tracked catheters that Boston Scientific will offer to the U.S. market. Type I atrial flutter is an abnormal rhythm of the upper chambers of the heart.